PamelaMunsterMD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

Join to view full profile

Dr. Munster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Munster's full profile

Already have an account?

Office
505 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2742
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
University of Bern Faculty of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 2008 - 2026
FL State Medical License 2001 - 2010
NY State Medical License 2000 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies Start of enrollment: 2004 Mar 01
Completed
Phase 1
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors Start of enrollment: 2009 Sep 13
Completed
Phase 1
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer Start of enrollment: 2008 Dec 10
Terminated
Phase 2
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors Start of enrollment: 2010 Jan 01
Completed
Phase 1
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Start of enrollment: 2010 Jul 20
Completed
Phase 1, Phase 2
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Start of enrollment: 2011 Oct 01
Completed
Phase 2
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Start of enrollment: 2012 Jun 25
Active, not recruiting
Phase 1
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Completed
Phase 1, Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) Start of enrollment: 2013 Nov 01
Completed
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
Completed
Phase 1
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies Start of enrollment: 2016 Dec 01
Terminated
Phase 1
64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets Start of enrollment: 2016 Apr 01
Withdrawn
Early Phase 1
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Start of enrollment: 2018 Jan 12
Completed
Phase 1
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Start of enrollment: 2021 Mar 11
Terminated
Phase 2
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Start of enrollment: 2021 Mar 31
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Cho, D., Gibney, G., Hodi, F., Jones, M., Bowman, J., Smith, M., Lakshminarayanan, M., O'Day, S., Munster, P., Iannotti, N., Kirkwood, J., Villaruz, L., Mettu, N.> ;Cancer Research Communications. 2023 Dec 19
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Albiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, Myung-Ju Ahn, Pamela Munster, George Blumenschein Jr, Benjamin Solomon, Darren Wan-Teck Lim, Ruey-Long Hong, D...> ;Targeted Oncology. 2023 Nov 1
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend?
Erica S Tsang, Pamela N Munster> ;JAMA Oncology. 2023 Jul 1
13 citations
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W Bowles, Hyunseok Kang, Barbara Burtness, Eric ...> ;Journal of Clinical Oncology. 2022 Dec 20
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Erica S Tsang, Rahul R Aggarwal, Emily K Bergsland, Edwin A Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mar...> ;Cancer Research Communications. 2022 Jul 1
6 citations
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, Erkut Borazanci, Manish R Sharma, Joseph M Custodio, Iulia Cristina Tudor, Hristina I Pashova, Stacie Peacock Sh...> ;Clinical Cancer Research. 2022 Aug 2
Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.
Emily W Modlin, Anne M Slavotinek, Thomas N Darling, Stanley Lipkowitz, Frederic G Barr, Pamela N Munster, Leslie G Biesecker, Christopher A Ours> ;American Journal of Medical Genetics. Part A. 2022 Sep 1
2 citations
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.
Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven Francis Powell, Pamela N Munster, Wen Wee Ma, Benedito A Carneiro, Bruno R Bastos, Stacy Mikrut, William Mikrut...> ;Neuro-Oncology Advances. 2022 Feb 7
1 citations
Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.
Erica S Tsang, Pamela N Munster> ;Oncotargets and Therapy. 2022 Jan 1
19 citations
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
James J. Harding, Melinda L. Telli, Pamela N. Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Christopher J. Molineaux, Keith W....> ;Clinical Cancer Research. 2021 Jul 20
3 citations
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C Logan, Matthew L. Settles, Gabriel ...> ;Blood Cancer Discovery. 2021 Jul 16
7 citations
Specialized computational methods for denoising, B 1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors.
Philip M. Lee, Hsin-Yu Chen, Jeremy W. Gordon, Zihan Zhu, Peder E. Z. Larson, Nicholas Dwork, Mark Van Criekinge, Lucas Carvajal, Michael A. Ohliger, Zhen J. Wang, Dua...> ;Magnetic Resonance in Medicine. 2021 Jul 3
7 citations
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Thomas G. Martin, Nina Shah, Joshua Richter, David H. Vesole, Sandy W. Wong, Chiung Yu Huang, Deepu Madduri, Sundar Jagannath, David S. Siegel, Noa Biran, Jeffrey L. W...> ;Cancer. 2021 Jun 1
11 citations
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alli...
Michael J. Jelinek, Nathan R. Foster, Alex J. Zoroufy, Gary K. Schwartz, Pamela N. Munster, Tanguy Y. Seiwert, Jonas A. De Souza, Everett E. Vokes> ;Oral Oncology. 2021 Mar 1
7 citations
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
Riyue Bao, Oliver Surriga, Daniel J Olson, Jacob B. Allred, Carrie Strand, Yuanyuan Zha, Timothy Carll, Brian W. Labadie, Bruno R. Bastos, Marcus O. Butler, David Hogg...> ;Melanoma Research. 2021 Feb 1
6 citations
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective G...
Rosario Pivonello, Pamela N Munster, Massimo Terzolo, Rosario Ferrigno, Chiara Simeoli, Soraya Puglisi, Utsav Bali, Andreas G Moraitis> ;Frontiers in Endocrinology. 2021 Jan 1
19 citations
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Jasgit C. Sachdev, Pamela N. Munster, Donald W. Northfelt, Hyo S. Han, Cynthia X. Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Y. Moore, Arunthathi Thia...> ;Breast Cancer Research and Treatment. 2021 Feb 1
26 citations
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Lillian L. Siu, Joshua Brody, Shilpa Gupta, Aurélien Marabelle, Antonio Jimeno, Pamela N. Munster, Juneko E. Grilley-Olson, Alain H. Rook, Antoine Hollebecque, Rebecca...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
587 citations
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The New England Journal of Medicine. 2020 Sep 20
93 citations
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Manuela Terranova-Barberio, Nela Pawlowska, Mark M. Moasser, Amy Jo Chien, Michelle E. Melisko, Hope S. Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael Rosenblum,...> ;Nature Communications. 2020 Jul 17
7 citations
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Anniina Färkkilä, Doga Gulhan, Julia Casado, Connor A. Jacobson, Huy V. Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Z...> ;Nature Communications. 2020 May 18
163 citations
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Anniina Färkkilä, Doga Gulhan, Julia Casado, Connor A. Jacobson, Huy V. Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Z...> ;Nature Communications. 2020 Mar 19
33 citations
Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)
Jason J. Luke, Daniel J Olson, Jacob B. Allred, Carrie Strand, Riyue Bao, Yuanyuan Zha, Timothy Carll, Brian W. Labadie, Bruno R. Bastos, Marcus O. Butler, David Hogg,...> ;Clinical Cancer Research. 2020 Feb 15
3 citations
Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials
Sarah B. Garrett, Thea Matthews, Corey M. Abramson, Christopher J. Koenig, Fay J. Hlubocky, Christopher K. Daugherty, Pamela N. Munster, Daniel Dohan> ;JCO Oncology Practice. 2020 Jan 1
3 citations
Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Andre De Souza, Fabio A. Tavora, Devalingam Mahalingam, Pamela N. Munster, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro> ;Frontiers in Immunology. 2020 Oct 19
Join now to see all

Lectures

Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).
2019 ASCO Annual Meeting - 6/1/2019
A phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors: The dose-finding phase.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkp...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Identical Twin Sisters Diagnosed with Identical Breast Cancer Within Weeks of One AnotherAugust 6th, 2019
Identical Mirror Twins Diagnosed with Similar Breast Cancer Just Weeks ApartAugust 6th, 2019
California: Identical Twins Diagnosed with Identical Breast Cancer Just Weeks ApartAugust 6th, 2019
Join now to see all